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Abstract
Background: The DNA damage by platinum cytostatics is thought to be the main cause of their
cytotoxicity. Therefore the measurement of the DNA damage induced by cis- and carboplatin
should reflect the sensitivity of cancer cells toward the platinum chemotherapeutics.
Methods: DNA damage induced by cis- and carboplatin in primary cells of ovarian carcinomas was
determined by the alkaline comet assay. In parallel, the reduction of cell viability was measured by
the fluorescein diacetate (FDA) hydrolysis assay.
Results: While in the comet assay the isolated cells showed a high degree of DNA damage after
a 24 h treatment, cell viability revealed no cytotoxicity after that incubation time. The individual
sensitivities to DNA damage of 12 tumour biopsies differed up to a factor of about 3. DNA damage
after a one day treatment with cis- or carboplatin correlated well with the cytotoxic effects after
a 7 day treatment (r = 0,942 for cisplatin r = 0.971 for carboplatin). In contrast to the platinum
compounds the correlation of DNA damage and cytotoxicity induced by adriamycin was low (r =
0,692), or did not exist for gemcitabine.
Conclusion: The measurement of DNA damage induced by cis- and carboplatin is an accurate
method to determine the in vitro chemosensitivity of ovarian cancer cells towards these
cytostatics, because of its quickness, sensitivity, and low cell number needed.
Background
Cis- and carboplatin used in the standard chemotherapy
of ovarian carcinomas possess DNA damaging properties.
The DNA damage by the platinum compounds is thought
to be the main cause of their cytotoxicity [1] whereby the
DNA damages result in inhibition of growth and subse-
quently in apoptosis and necrosis [2]. It was shown that
the platinum-DNA adducts directly correlate with the dis-
ease response [3]. Therefore, the measurement of the DNA
damage induced by cis- and carboplatin in ovarian carci-
noma cells should reflect the sensitivity of these cells
toward the platinum chemotherapeutics.
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DNA damage in single cells can be determined by several
standard methods like measuring chromosome aberra-
tions (CA), micronucleus test (MNT), or the comet assay.
In contrast to the comet assay, the CA test and the MNT
can only be used for dividing cells. Because of the low
division rate of primary ovarian cancer cells in vitro the
comet assay seems to be the method of choice as a rapid
and highly sensitive test for the determination of DNA
damages in cells of ovarian cancer biopsies. In the alkaline
comet assay directly induced single strand breaks can be
detected as well as alkaline labile sites and enzymatically
induced strand breaks by DNA repair endonucleases [4,5].
DNA crosslinks of cis- and carboplatin can be indirectly
determined by introducing single strand breaks in plati-
num treated DNA via x-rays or strand breaking chemicals
like methyl methanesulfonate (MMS) [6]. The reduction
of the single strand breaks provoked by e.g. MMS alone
quantitatively reflects the crosslinks induced by the plati-
num compounds. Even though the portion of interstrand
crosslinks is only 1-2% of all the DNA damage induced by
cis- and carboplatin [1,7] the constant ratio of the adducts
allows the representative determination of all DNA dam-
ages by measuring the interstrand crosslinks only.
If DNA damage induced by cis- and carboplatin is the
main cause for cytotoxicity a strong correlation between
both parameters is expected. Under these conditions, a
correlation of DNA damage and clinical outcome is
expected too because a correlation between cytotoxicity
and clinical outcome was repeatedly shown [8-12]. There-
fore, we determined DNA damage as well as cytotoxicity
after treatment of the isolated cells from ovarian cancer
biopsies with cis- and carboplatin. In addition to the plat-
inum compounds, we also determined the DNA damage
and cytotoxicity provoked by adriamycin and gemcitab-
ine, two chemotherapeutics also used in the treatment of
recurrent ovarian carcinomas. It is known that both com-
pounds possess a broad spectrum of cell damaging prop-
erties besides the DNA damage [13,14]. Here, we expected
a lower correlation between DNA damage and cell viabil-
ity compared to the platinum compounds. Last but not
least, we determined the variability in the sensitivity of 12
biopsies of ovarian carcinomas towards cis- and carbopl-
atin. The problem of resistance of ovarian cancer cells
especially after a first line chemotherapy has been
described [8]. For the oncologist the knowledge of plati-
num sensitivity of the individual tumours would be
important to take his choice of cytostatics for the second
line therapy.
The aim of this study was to elucidate if the determination
of platinum induced DNA damage in the comet assay, is
an appropriate tool to rapidly recognize the individual
platinum sensitivity of cells from ovarian cancer patients.
Methods
Chemicals
Gemcitabine (GEMZAR®, 200 mg) was obtained from
Lilly, Gießen, F.R.G., cisplatin (PLATINEX®, 0.5 mg/ml)
from Bristol-Myers Squibb, München, F.R.G, adriamycin
(DOXORUBICIN®, 2 mg/ml) from Hexal, Holzkirchen,
Germany and carboplatin (Carbomedac®, 10 mg/ml)
from Medac, Wedel, Germany. Methyl methanesulfonate
was purchased from Fluka, Buchs, Switzerland. Colla-
genase A, DNase and dispase II were provided by Roche,
Mannheim, F.R.G. Cell culture medium (quantum 333)
was purchased from PAA, Pasching, Austria.
Isolation of cancer cells and cell culture
Cancer biopsies were obtained from patients with primary
or recurrent epithelial ovarian cancer, identified by histo-
logical and cytological examination. Specimens were
obtained according to protocols approved by the hospital
institutional Review Board and the institutional ethical
guidelines, after patient informed consent was received.
For transport lasting 30-90 min, specimens were placed
into sterile flasks containing medium enriched with 5%
penicillin/streptomycin. Under sterile conditions biopsies
were dispersed in 0.5 - 2.0 mm3 fragments after excision of
fat tissue. Fragments were then dissociated to a cell sus-
pension of single cells by incubation in 5-10 ml enzymatic
dissociation solution (collagenase/DNase) for 1-2 hours
at 37°C on a shaker at 800 rpm. Small cell aggregates were
excluded by filtration (0.2 μm pore size). Thereafter eryth-
rocyte lysis reagent was repeatedly added to eliminate
erythrocytes. Cells were washed twice with medium and
seeded for the experiment. The viability of the isolated
cells was 85-95% measured by trypane blue dye exclusion.
Cytotoxicity measurement (FDA assay)
The FDA assay is based on measurement of fluorescence
generated by enzymatic hydrolysis of fluorescein diacetate
(FDA) to fluorescein which is retained within the living
cells. The FDA assay was performed according to Rotman
and Papermaster [15], modified by Larsson et al.[9]. Treat-
ment with the chemotherapeutics dissolved in Quantum
333 occured 36 hours after seeding of 6000 cells/well of a
96 well plate at 37°C, 5% CO2/95% air with more than
95% humidity. Five concentrations of each drug with four
replicates were tested. Peak serum concentrations were
used (cisplatin: 100% peak serum concentration = 12,6
μM, carboplatin: 100% peak serum concentration = 42,5
μM, adriamycin: 100% peak serum concentration = 919,9
nM, gemcitabine: 100% peak serum concentration = 80,8
μM). After an exposure of 7 days the drug containing
medium was removed and 200 μl/well FDA solution (1
μg/ml in phosphate buffered saline) were added for one
hour and incubated at 37°C, 5% CO2/95% air with more
than 95% humidity. Thereafter the fluorescence was
measured with a microplate fluorescence reader (FLUOs-BMC Cancer 2009, 9:359 http://www.biomedcentral.com/1471-2407/9/359
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tar, Offenbach, F.R.G.) with an excitation of 485 nm and
an emission of 538 nm. Fluorescence data were analyzed
using SPSS 11.5.1.
Genotoxicity measurement (Comet assay)
The comet assay was performed according to Tice et al.
[16]. Briefly, 4.000-10.000 cells/well were seeded into 24-
well plates. 36 hours after seeding, the cells were treated
with the chemotherapeutic agents. Drug incubation was
conducted for 24 hours. DNA damage induced by the
crosslinkers cis- and carboplatin was indirectly measured
in the comet assay. Therefore, it was detected by adding
the DNA strand breaking agent methyl methanesulfonate
(MMS, 0.9 mM) during the last hour of incubation. The
reduction of DNA strand breaks induced by MMS quanti-
tatively reflects the DNA crosslinks induced by cis- and
carboplatin [6]. After chemical treatment, cells were
washed twice, trypsinized and resuspended in 40 μl ice-
cold PBS-buffer. A volume of 20 μl of the resuspended
cells was mixed with 80 μl 0.5% low melting agarose at
37°C and applied to pretreated microscope slides.
Pretreatment of slides involved coating with 1.5% agar-
ose, diluted in Ca2+ and Mg2+- free PBS (phosphate buff-
ered saline, pH 7,4). Each concentration was performed in
duplicate. The slides mounted with cells were covered
with coverslips and kept in the refrigerator for 3-5 min to
solidify the low melting agarose. The following steps were
performed under dim-light to prevent additional UV-
induced DNA damage. After removing the coverslips,
slides were immersed in 4°C cold lysing solution pH 10.0
(2,5 M NaCl, 100 mM EDTA, 10 mM Tris, 1% N-lauroyl
sarcosine, 1% Triton X100, 10% DMSO; the last two com-
pounds were added freshly). Slides were kept at 4°C for 1
h. After lysis, the slides were placed on a horizontal elec-
trophoresis box. The unit was filled with freshly prepared
alkaline buffer (300 mM NaOH, 1 mM EDTA, pH 13),
until slides were completely covered with buffer. After an
incubation for 40 min at 4°C in alkaline buffer, to allow
DNA unwinding and DNA breakage at alkali labile sites,
DNA electrophoresis was performed in an ice bath at 25 V
and 300 mA for 20 min. After electrophoresis, the slides
were covered with neutralization buffer (0.4 M Tris HCl,
pH 7.5) for 5 min. This step was repeated twice. Thereaf-
ter, the slides were briefly dipped into water and dried by
air overnight. Finally, 40 μl ethidium bromide (20 μg/ml)
was added to each slide. Slides were covered with a cover-
slip and kept for 5 min in the dark for DNA staining. DNA
migration was analyzed by fluorescence microscopy
(Nikon, Eclipse E600W). The tail moment (tm) was deter-
mined using the software "Lucia comet assay single stain"
(Nikon). The tm considers the length of the tail as well as
the intensity of the fluorescence staining of the tail, com-
pared to the staining of the comet core. From each con-
centration, 50 randomly selected cells (25 cells from each
of two duplicate slides) were analyzed. For statistical anal-
ysis, Mann-Whitney-U-Test was performed using SPSS
11.5.1
Results
Freshly isolated cells of biopsies from patients with ovar-
ian carcinomas were examined in their sensitivities
towards cis- and carboplatin. To optimize the experimen-
tal conditions time and concentration dependent cyto-
and genotoxicity was measured.
The time dependent geno- and cytotoxic effect of carbo-
and cisplatin was determined up to 7 days. The results for
cisplatin are shown in Fig. 1A, and for carboplatin in Fig.
1B. After a 24 h incubation with cisplatin nearly 80% of
the measurable DNA damage had occurred. It increased to
87% at day 7. The DNA damage of 60% induced by carbo-
platin was somewhat lower than that of cisplatin after a
one day incubation. After day 7 genotoxicity was similar
for both compounds. The high degree of DNA damage
after a 24 h incubation was nearly non-cytotoxic (Fig. 1),
but the cisplatin cytotoxicity increased at day 2, and at day
6 a reduction of the cell viability of 85% was observed (Fig
1A). Carboplatin was less toxic than cisplatin. Cytotoxic-
ity was observed at day 4 and reached a reduction of cell
viability to 35% at day 6 (Fig. 1B).
The concentration dependence of DNA damage and cyto-
toxicity induced by the platinum compounds is shown
Fig. 2. The DNA damage after a 24 h incubation with cis-
(Fig. 2A) and carboplatin (Fig. 2B) was compared with the
cytotoxicity obtained after a 7 day treatment. Genotoxicity
was detected at the lowest concentration measured
(12,5% peak serum concentration) and up. At 100% peak
serum concentration the curves show a saturation level
with 85% DNA damage for cisplatin and 70% for carbo-
platin. A doubling of the concentration did not signifi-
cantly enhance DNA damage
This may be explained by reaching the upper detection
limit of 100%. Cell viability continuously decreased to
3% at 200% peak serum concentration for cisplatin and to
30% for carboplatin.
After we had optimized the basic parameters measuring
the DNA damage induced by cis- and carboplatin 12 biop-
sies of patients with ovarian cancer were examined. The
results of a 24 hour treatment with 50% peak serum con-
centration of cis- or carboplatin are shown in Fig. 3. The
DNA damaging potential of cisplatin was in 11 biopsis
higher than that of carboplatin. The cellular sensitivities
to cis- or carboplatin differed by a factor of about 3. Sim-
ilar differences were also observed measuring the reduc-
tion of viability (data not shown).BMC Cancer 2009, 9:359 http://www.biomedcentral.com/1471-2407/9/359
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In addition to the platinum compounds the DNA damag-
ing effects of adriamycin and gemcitabine were measured.
Both cytostatics also provoked DNA damage after a 24 h
incubation in a concentration dependent manner (Fig. 4
and 5). While in increasing concentrations adriamycin
enhanced cytotoxicity (Fig. 4A) gemcitabine did not (Fig.
4B). At the lowest concentration measured (6.25% peak
serum concentration) gemcitabine reduced cell viability
to 25% after a 7 day incubation. This was not further
reduced by higher concentrations of gemcitabine.
If DNA damage induced by cytostatics would be the main
cause of their cytotoxicity, a good statistical correlation of
DNA damage and viability would be expected. For cis-
and carboplatin the correlation of DNA damage (1 day
treatment) and cell viability (7 day treatment), measured
in concentrations ranging from 6,25%- to 200% peak
serum concentration, is shown in Fig. 5. A good correla-
tion r2 = 0.942 for cisplatin (Fig. 5A) and r2 = 0.971 for car-
boplatin (Fig. 5B) from 12 biopsies was obtained. For
adriamycin and gemcitabine only 7 biopsies were exam-
ined. Here the correlation was extremely low (Fig. 6A)
with r = 0,691 for adriamycin, and was nonexistent for
gemcitabine (Fig. 6B).
Discussion
Carbo- and cisplatin are generally used in combination
with paclitaxel in the first line standard chemotherapy of
ovarian carcinomas. In the second line therapy these plat-
inum compounds are often administered again without
knowing if the cancer cells are resistant, or of lowered sen-
sitivity toward those chemotherapeutics. From 12 biop-
sies tested in this study a difference in the platinum
sensitivities up to a factor of 3 was measured. It is there-
fore of great importance to know in advance the sensitiv-
ity of the individual cancer cells before a second line
therapy is started.
To determine the sensitivity of ovarian cancer cells toward
platinum compounds several methods were described
like measurement of cell viability [8-12,17,18], of predic-
tive marker genes [19], relevant genomics [19,20], or pro-
teomics [21]. From these methods the determination of
cell viability is the most often used test which is also com-
mercially available [22]. Of the cell viability assays for
studying in vitro chemosensitivity the FDA assay was
favoured here over the ATP assay because only in the FDA
assay dead and live cells can be visualized, so that possible
subclones of resistant cells are recognized and eliminated.
For both cytotoxicity assays a correlation with the clinical
outcome was shown [8-12].
Time dependent DNA damage (black square) presented as median with first and third quartile and cytotoxicity (black triangle)  presented as mean with standard deviation induced by 100% SPK cisplatin (A), or 100% SPK carboplatin (B) in primary ovarian  carcinoma cells Figure 1
Time dependent DNA damage (black square) presented as median with first and third quartile and cytotoxic-
ity (black triangle) presented as mean with standard deviation induced by 100% SPK cisplatin (A), or 100% SPK 
carboplatin (B) in primary ovarian carcinoma cells. DNA damage is shown as reduction of MMS induced tail moments 
(tm) by the platinum compound (50 comets/sample evaluated). MMS alone induced a tail moment ranging from 80-90. The plat-
inum compounds alone induced no tail moments.BMC Cancer 2009, 9:359 http://www.biomedcentral.com/1471-2407/9/359
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A critical point of the viability assays is the long ex vivo
incubation of 5-6 days not knowing if the behaviour of
the cells toward chemotherapeutics is changing. We used
the comet assay to measure genotoxicity in 2 days. Within
this time interval cell transformations are unlikely.
Martelli [23] observed DNA damages already after a 4
hours incubation with platinum compounds in therapeu-
tic relevant concentrations. The 24 h incubation in our
experiments yielded more than 75% of DNA damage of
the maximal DNA damage (obtained after 7 days incuba-
tion). This demonstrates the high sensitivity of the comet
assay. Cisplatin was more geno- and cytotoxic than carbo-
platin. This is in accordance with data from literature
[23,24]. Significant cytotoxicity was not observed before
day 2 of incubation with a 100% peak serum concentra-
tion cisplatin and 4 day for carboplatin. The negligible
cytotoxicity after a one day incubation is important to
avoid false positive results in the comet assay. It was
shown that cytotoxicity > 30% can induce comet forma-
tion also by non-genotoxic compounds [25,26].
To correlate DNA damage with cytotoxicity the optimum
of incubation time of each assay was used. This was a 24
h incubation for measuring genotoxicity and a 7 day incu-
bation for cytotoxicity. It may be argued that individual
DNA repair phenomena were not completely considered
during the short test period of one day although the indi-
vidual DNA repair may play a role in the chemosensitivity
of the patients toward the platinum compounds. It was
manifold described that the efficacy of platinum com-
pounds in ovarian cancer is influenced by many factors
including decreased accumulation or enhanced detoxifi-
cation [27,28]. These factors are covered by a 24 h geno-
toxicity measurement. It was shown that the clinical
outcome of patients with ovarian carcinoma correlates
with Cu-transporting uptake of ATPase [29] and P-glyco-
protein expression [30], both responsible for platinum
uptake. Furthermore, a correlation of clinical data and
deactivation of platinum compounds within the cell via
glutathione S transferase pi [31,32] or metallothionein
[33] was observed. The sum of these factors may superim-
pose the influence of DNA repair. Therefore, individual
DNA repair (which in our test is only comprised of the
repair during the 24 h incubation time) seems to play a
minor role in the correlation of DNA damage and cytotox-
icity. If the individual DNA repair would be that impor-
tant, we could not explain the observed correlation of
DNA damage and cytotoxicity.
The correlation analysis revealed a strong correlation
between DNA damage and cell viability for cis- and carbo-
platin. This result leads to two conclusions. First, both
assays independent of each other were suitable for deter-
Concentration dependent DNA damage (black square) presented as median with first and third quantile, and cytotoxicity  (black triangle) presented as mean with standard deviation, induced by cisplatin (A), or carboplatin (B) Figure 2
Concentration dependent DNA damage (black square) presented as median with first and third quantile, and 
cytotoxicity (black triangle) presented as mean with standard deviation, induced by cisplatin (A), or carbopla-
tin (B). DNA damage was measured after a 24 h incubation, cytotoxicity after a 7 day incubation with the cytostatics. MMS 
alone induced a tail moment ranging from 80-90. The platinum compounds alone induced no tail moments.
Concentration dependent DNA damage (black square) presented as median with first and third quantile, and cytotoxicity  (black triangle) presented as mean with standard deviation, induced by cisplatin (A), or carboplatin (B) Figure 2
Concentration dependent DNA damage (black square) presented as median with first and third quantile, and 
cytotoxicity (black triangle) presented as mean with standard deviation, induced by cisplatin (A), or carbopla-
tin (B). DNA damage was measured after a 24 h incubation, cytotoxicity after a 7 day incubation with the cytostatics. MMS 
alone induced a tail moment ranging from 80-90. The platinum compounds alone induced no tail moments.BMC Cancer 2009, 9:359 http://www.biomedcentral.com/1471-2407/9/359
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mining the sensitivity of ovarian cancer cells towards the
platinum compounds. Secondly DNA damage must be
the main if not the only cause for cytotoxicity as described
by other authors [2]. Reed et al. [1] demonstrated that the
formation of cis- and carboplatin-DNA adducts in leuco-
cytes of ovarian cancer patients correlated well with the
clinical response. This supports our findings that measure-
ment of DNA damage induced by the platinum com-
pounds reflects the response to the chemotherapy.
In contrast to the platinum compounds, DNA damage
induced by gemcitabine or adriamycin did either not cor-
relate with the cytotoxicity, or the correlation was low. For
both cytostatics multiple molecular effects are known.
Radical formation, inhibition of several enzymes like
topoisomerase I and II, helicases and some polymerases
were described for adriamycin [34-36]. Gemcitabine
influences several metabolic ways in the cell like DNA
synthesis, RNA synthesis and DNA repair [37]. All these
adverse effects will influence cytotoxicity. Therefore, DNA
damage by adriamycin and gemcitabine is only one effect
of many others. Thus, a correlation of cytotoxicity with
only one of these parameters, like the DNA damage, could
not be observed. To use the comet assay for cellular chem-
osensitivity testing of other chemotherapeutics, like oxaz-
ophosphorines, nitrosoureas, actinomycin D, or
mitomycin C, it is at first necessary to verify the positive
correlation between cyto- and genotoxicity for each com-
pound, individually, as shown here for cis- and carbopla-
tin.
In conclusion
The comet assay is a suitable method for determining the
sensitivity of ovarian cancer cells toward cis- and carbopl-
atin. The comet assay has some advantages over the often
used in vitro chemosensitivity tests measuring cytotoxic-
ity. In the comet assay described here, the results are
obtained two days after receiving the cancer biopsy, in
contrast to 5-6 days in the ATP cytotoxicity test [16].
Therefore, changes in the behaviour of the cancer cells ex
vivo can be minimized. Another advantage is the low cell
number needed for the comet assay. It is possible to meas-
ure only one concentration (50% peak serum concentra-
tion), while in the cell viability assay one has to determine
a dose effect curve with four parallel samples per concen-
tration [21]. Using 96 well plates with 3.000 cells per well,
DNA damage by a 24 hour incubation of cisplatin (white bars) and carboplatin (dark bars) in ovarial cancer cells from 12 biop- sies presented as median with first and third quartile Figure 3
DNA damage by a 24 hour incubation of cisplatin (white bars) and carboplatin (dark bars) in ovarial cancer 
cells from 12 biopsies presented as median with first and third quartile. The platinum concentration was 50% peak 
serum. MMS alone induced a tail moment ranging from 80-90. The platinum compounds alone induced no tail moments.BMC Cancer 2009, 9:359 http://www.biomedcentral.com/1471-2407/9/359
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Concentration dependent DNA damage (black square) presented as median with first and third quartile, and cytotoxicity  (black triangle) presented as mean with standard deviation, induced by adriamycin (A) and gemcitabine (B) Figure 4
Concentration dependent DNA damage (black square) presented as median with first and third quartile, and 
cytotoxicity (black triangle) presented as mean with standard deviation, induced by adriamycin (A) and gem-
citabine (B). DNA damage was measured after a 24 h incubation, cytotoxicity after a 7 day incubation.
Correlation of DNA damage in ovarian cancer cells induced by cisplatin (A) (24 h treatment; r = 0,9422), or carboplatin (B) (24  h treatment; r = 0,9711) and cytotoxicity (induced by a 7 day treatment) Figure 5
Correlation of DNA damage in ovarian cancer cells induced by cisplatin (A) (24 h treatment; r = 0,9422), or 
carboplatin (B) (24 h treatment; r = 0,9711) and cytotoxicity (induced by a 7 day treatment). Data were obtained 
from 12 biopsies.BMC Cancer 2009, 9:359 http://www.biomedcentral.com/1471-2407/9/359
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about 18.000 cells were needed for the comet assay. It
means that needle biopsies are sufficient to determine the
sensitivity of these cancer cells. This is important espe-
cially for small recurrent cancer biopsies and metastases
where only needle biopsies are available.
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